Sanofi Pasteur and Statens Serum Institut Team Up Against Tu...(and for SSI. SSI is one of the world's l...)

Date:2/14/2008

and for SSI. "SSI is one of the world's leading producers of BCG and has for more than a century worked within the field of prevention and control of TB. We are excited to team up our research with one of the world's largest vaccine manufacturers. The combination of both parties' leading vaccine expertise will really be able to make a difference in the development of a novel TB vaccine for the benefit of the world's poorest people."

The only TB vaccine (BCG--attenuated Bacille Calmette Guerin) used in the world today was developed over 80 years ago. A TB vaccine is especially important in areas of the world where TB is highly prevalent and the chances of an infant or young child becoming exposed to an infectious case are high. Although BCG is effective in protecting infants against childhood forms of the disease, a more effective vaccine is needed for protection of adolescents and adults against pulmonary tuberculosis.

Professor Paul-Henri Lambert of the Centre of Vaccinology, University of Geneva, and Chairman of the TBVAC consortium steering committee, agrees that to effectively control TB, a new or improved vaccine must be developed as an alternative to or a complement of BCG. "The development of an improved TB vaccine has been a challenging goal for decades, but significant scientific advances have been made over the past 15 years that bring us closer than ever before to achieving this goal," explains Dr. Lambert. "Results obtained with recombinant protein TB vaccine candidates in pre-clinical studies are promising, and I am very optimistic about this approach leading to a new TB vaccine."

About Tuberculosis(2)

More than eight million people develop active TB annually, and approximately two million die from the disease each year. The World Health Organization estimates that there are more than 14 million people living with TB. Those with active TB who receive no treatment can infect an average of 10 to 15 people annually.

Most
'/>"/>

SOURCE Sanofi Pasteur Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
3. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
4. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Pasteuria Bioscience Taps New CEO David N. Duncan
6. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
7. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
8. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
9. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
10. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
11. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)